In Current drug targets
With this article, we would like to take the reader on a journey into the world of molecular medicine as it has evolved over the past decades enabled by advances in genomics. These findings advanced both the development of prognostic parameters and the evolvement of therapy strategies. In this manuscript, we will present haematopoietic diseases as a prime example for this progress because they are relevant not only for their frequency but also for the evident diagnostic and therapeutic progress. The growing understanding of the underlying pathophysiology originates from the cellular pathology as it was described by, e.g., RUDOLF VIRCHOW (1821-1902). The identification of specific genomic changes in haematological malignancies and solid tumour diseases provided us with very sensitive tools for diagnostics and prediction of prognosis. Thus, it paved the way to individualized or personalized therapy. In particular, the rapid development of sequencing techniques for the human genome using Next Generation Sequencing (NGS) has contributed to this progress. Recently, artificical intelligence provided us with the tools to analyze the complex interactions of genomic alterations, course of disease, and further factors of as yet unknown significance. With all these indisputable improvements, we should not neglect the holistic treatment mandate of personalized therapy, i.e., therapy appropriate to the individual. In this context, the treating physician should address relevant co-morbidities, the psychosocial embedding of the patient and his desire for treatment.
Jäger Paul, Twarock Sören, Haas Rainer
allogeneic stem cell transplantation.\n, artificial intelligence, diagnostic, myeloid malignancies, next generation sequencing, prognosis, targetsed therapies